Annual Report 2012

More documents

Recommendations

Info

Loss on impairment of fixed assets and Unamortized balance of goodwill by business segments were as follows: Loss on impairment of 45 Nipro Corporation Annual Report 2012 Millions of yen Millions of yen 2012 2011 Reportable Segment Reportable Segment Other Total Medical Pharmacetical Materials Total Medical Pharmacetical Materials Total Other Total fixed assets ··············· ¥ 529 ¥ — ¥ — ¥ 529 ¥ — ¥ 529 ¥ 39 ¥ — ¥ 26 ¥ 65 ¥ — ¥ 65 Unamortized balance of goodwill ···················· 11,539 (3) 359 11,895 — 11,895 7,287 198 349 7,834 — 7,834 Thousands of U.S. dollars (Note 1) 2012 Reportable Segment Medical Pharmacetical Materials Total Other Total Loss on impairment of fixed assets ··············· Unamortized balance of $ 6,436 $ — $ — $ 6,436 $ — $ 6,436 goodwill ···················· 140,394 (36) 4,368 144,726 — 144,726 Net sales and Property, plant and equipment by geographic area were as follows: Millions of yen Millions of yen 2012 2011 Japan America Europe Asia Total Japan America Europe Asia Total Net sales ······················ Property, plant and ¥ 129,237 ¥ 40,519 ¥ 23,140 ¥ 19,117 ¥ 212,013 ¥ 124,905 ¥ 37,121 ¥ 20,707 ¥ 13,210 ¥ 195,943 equipment ················· 102,275 8,392 3,311 31,701 145,679 105,022 5,779 141 17,564 128,506 Thousands of U.S. dollars (Note 1) 2012 Japan America Europe Asia Total Net sales ······················ Property, plant and $ 1,572,417 $ 492,992 $ 281,543 $ 232,595 $ 2,579,547 equipment ················· 1,244,373 102,105 40,285 385,704 1,772,467
15. Selling, General and Administrative Expenses Significant components of selling, general and administrative expenses for the years ended March 31, 2012 and 2011 are as follows: Millions of yen Thousands of U.S. dollars (Note 1) 2012 2011 2012 Salaries ··································································································· ¥ 11,372 ¥ 10,358 $ 138,362 Freight charges ························································································ 5,143 4,685 62,575 16. Reseach and Development Expenses Research and development expenses for the years ended March 31, 2012 and 2011 were ¥5,957 million (US$72,478 thousand) and ¥4,977 million, respectively. 17. Supplemental Disclosures of Cash Flow Information Supplemental information related to the Consolidated Statements of Cash Flows was as follows: Millions of yen Thousands of U.S. dollars (Note 1) 2012 Cash paid during the year for: 2011 2012 Interest ······························································································ ¥ 3,226 ¥ 2,405 $ 39,251 Income tax ························································································ 6,147 8,217 74,790 Nipro Corporation Annual Report 2012 46
Page 1 and 2: Annual Report 2012 Year Ended March
Page 3 and 4: Consolidated Financial Highlights N
Page 5 and 6: On the occasion of the appointment
Page 7 and 8: profit-sharing is conducted in acco
Page 9 and 10: Pharmaceutical Main Products • In
Page 11 and 12: Message Managing Director Kazuo Wak
Page 13 and 14: Asia 41.9% Rate of Growth Measured
Page 15 and 16: 2. Pharmaceutical Business Currentl
Page 17: (2) Domestic Subsidiaries As of Mar
Page 20 and 21: Status of Corporate Governance 1. S
Page 22 and 23: CSR Nipro is able to conduct its bu
Page 24 and 25: Financial Review Overview In the cu
Page 26 and 27: the increase in income before incom
Page 29 and 30: Thousands of Millions of yen U.S. d
Page 31 and 32: Millions of yen Thousands of U.S. d
Page 34 and 35: Consolidated Statements of Cash Flo
Page 36 and 37: (f) Investment Securities Investmen
Page 38 and 39: 5. Pledged Assets The following ass
Page 40 and 41: 8. Financial Instruments (1) Circum
Page 42 and 43: 9. Derivatives The Company and its
Page 44 and 45: 13. Net Assets The significant prov
Page 48 and 49: Report of Independent Auditors 47 N
Page 50: NIPRO CORPORATION 3-9-3 Honjo-nishi

Annual Report 2012

Create successful ePaper yourself

Delete template?

Save as template?